{
  "id": 12792933,
  "title": "Shanghai Allist shares slide after U.S. partner’s lung cancer drug trial fails",
  "url": "https://urgent.news/2026/10/08/shanghai-allist-shares-slide-after-u-s-partners-lung-cancer-drug",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-08T05:08:37.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/shanghai-allist-shares-slide-after-us-partners-lung-cancer-drug-trial-fails-4937900"
  },
  "original_language": "en",
  "account": "Shanghai Allist Pharmaceuticals' shares plummeted 20% to the daily limit on Thursday following its U.S. partner Arrivent Biopharma's announcement that a late-stage lung cancer drug trial failed to meet its primary objective. The Shanghai-listed firm's stock slid to a low of 89.26 yuan by 05:07 GMT, marking its lowest point since June 24. Arrivent disclosed on Tuesday that the Phase 3 FURVENT trial, which assessed a new lung cancer drug called firmonertinib, did not demonstrate a statistically significant improvement in progression-free survival among patients with non-small cell lung cancer carrying specific EGFR gene mutations. The median progression-free survival for the 240 mg dose was 11 months, compared to 9.5 months for standard chemotherapy, with a hazard ratio of 0.75 and a p-value of 0.0654. Although the drug showed some positive effects on secondary measures, overall survival data remained inconclusive. Importantly, Arrivent found no new safety concerns associated with the drug.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}